Literature DB >> 10649446

Protein-protein interaction of FHL2, a LIM domain protein preferentially expressed in human heart, with hCDC47.

K K Chan1, S K Tsui, S M Ngai, S M Lee, M Kotaka, M M Waye, C Y Lee, K P Fung.   

Abstract

In the yeast two-hybrid library screening, the heart-specific FHL2 protein was found to interact with hCDC47. In vitro interaction study between FHL2 protein and hCDC47 was demonstrated. From the results of domain studies by the yeast two-hybrid assay, the second and third LIM domains in conjunction with the first half LIM domain of FHL2 were identified to be important in binding with hCDC47. Besides, in Northern blot hybridization of human cancer cell lines, the highest FHL2 mRNA expression was detected in colorectal adenocarcinoma SW480 and HeLa cell S3. Our results imply that FHL2 protein may associate with cancer development and may act as a molecular adapter to form a multicomplex with hCDC47 in the nucleus, thus it plays an important role in the specification or maintenance of the terminal differentiated phenotype of heart muscle cells. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10649446

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  10 in total

Review 1.  Eukaryotic MCM proteins: beyond replication initiation.

Authors:  Susan L Forsburg
Journal:  Microbiol Mol Biol Rev       Date:  2004-03       Impact factor: 11.056

2.  The Immunohistochemical Expression of MCM-3, -5, and -7 Proteins in the Uterine Fibroids.

Authors:  Piotr Rubisz; Lidia Hirnle; Christopher Kobierzycki
Journal:  Curr Issues Mol Biol       Date:  2021-07-25       Impact factor: 2.976

3.  The four and a half LIM family members are novel interactants of the human T-cell leukemia virus type 1 Tax oncoprotein.

Authors:  Áine McCabe; Kenichi Hashimoto; William W Hall; Noreen Sheehy
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

Review 4.  The FHL2 regulation in the transcriptional circuitry of human cancers.

Authors:  Cyanne Ye Cao; Simon Wing-Fai Mok; Vincent Wing-Sang Cheng; Stephen Kwok-Wing Tsui
Journal:  Gene       Date:  2015-07-26       Impact factor: 3.688

5.  Interaction of TACC proteins with the FHL family: implications for ERK signaling.

Authors:  Brenda Lauffart; Gautam V Sondarva; Omkaram Gangisetty; Melissa Cincotta; Ivan H Still
Journal:  J Cell Commun Signal       Date:  2007-03-28       Impact factor: 5.782

6.  Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway.

Authors:  Lihua Ding; Zhaoyun Wang; Jinghua Yan; Xiao Yang; Aijun Liu; Weiyi Qiu; Jianhua Zhu; Juqiang Han; Hao Zhang; Jing Lin; Long Cheng; Xi Qin; Chang Niu; Bin Yuan; Xiaohui Wang; Cui Zhu; Yan Zhou; Jiezhi Li; Haifeng Song; Cuifen Huang; Qinong Ye
Journal:  J Clin Invest       Date:  2009-01-12       Impact factor: 14.808

7.  DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis.

Authors:  F A Scholl; P McLoughlin; E Ehler; C de Giovanni; B W Schäfer
Journal:  J Cell Biol       Date:  2000-10-30       Impact factor: 10.539

8.  The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts.

Authors:  Bernd Martin; Richard Schneider; Stefanie Janetzky; Zoe Waibler; Petra Pandur; Michael Kühl; Jürgen Behrens; Klaus von der Mark; Anna Starzinski-Powitz; Viktor Wixler
Journal:  J Cell Biol       Date:  2002-10-07       Impact factor: 10.539

Review 9.  Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases.

Authors:  Ana Maria Olivares; Oscar Andrés Moreno-Ramos; Neena B Haider
Journal:  J Exp Neurosci       Date:  2016-05-05

10.  Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancer.

Authors:  L Verset; J Tommelein; X Moles Lopez; C Decaestecker; M Mareel; M Bracke; I Salmon; O De Wever; P Demetter
Journal:  Br J Cancer       Date:  2013-06-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.